Masimo (MASI) Given Daily Coverage Optimism Score of 0.15
News articles about Masimo (NASDAQ:MASI) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Masimo earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.1447813497775 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Masimo Announces CE Marking of Eve? CCHD Newborn Screening – WBTW – Myrtle Beach and Florence SC (wbtw.com)
- Masimo Announces CE Marking of Eve™ CCHD Newborn Screening Application for the Rad-97™ Pulse CO-Oximeter – Business Wire (press release) (businesswire.com)
- Masimo (MASI) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Masimo Announces CE Marking of Eve™ CCHD Newborn Screening Application for the Rad-97™ Pulse CO-Oximeter® (finance.yahoo.com)
- Masimo Co. (MASI) Director Sanford Fitch Sells 2,000 Shares (americanbankingnews.com)
Masimo (MASI) opened at $85.68 on Thursday. The company has a market cap of $4,498.49, a PE ratio of 13.56, a price-to-earnings-growth ratio of 3.31 and a beta of 0.85. Masimo has a one year low of $75.06 and a one year high of $104.71.
In other news, EVP Yongsam Lee sold 5,900 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $88.31, for a total transaction of $521,029.00. Following the completion of the sale, the executive vice president now owns 70,800 shares of the company’s stock, valued at $6,252,348. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $93.07, for a total transaction of $186,140.00. Following the sale, the director now directly owns 68,249 shares of the company’s stock, valued at approximately $6,351,934.43. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,098 shares of company stock valued at $4,315,261. Corporate insiders own 16.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.watchlistnews.com/masimo-masi-given-daily-coverage-optimism-score-of-0-15/1852100.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.